Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
Natalie Denburg · NCT03954899
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 56–85 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 230
- US sites recruiting
- 1
- Study start
- November 12, 2019
- Record last updated
- September 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-). AD biomarkers will be measured from cerebrospinal fluid (CSF) obtained from lumbar punctures. Cognitive function will be evaluated with routine neuropsychological tests.
AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.
Being studied: melatonin; placebo
Conditions: Mild Cognitive Impairment; Cognitive Decline; Healthy Aging
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- between ages of 56-85 years
- all participants must score 18 or above on Montreal Cognitive Assessment (MoCA);
- all participants must have a clinical dementia rating (CDR) Sum of boxes \<1;
- need to be willing to undergo CSF LP on two occasions over the course of their participation,
- need to be able and willing to stop using any prescription or non-prescription sleep aids (e.g.(e.g. Ambien, Sonata, Lunesta, Belsomra, Rozerem, Halcion, Intermezzo, Doxepin, Melatonin, etc.) for the duration of the study except for study-issued medications
- BMI \< 35 at the time of enrollment
- willing to bring a study partner (spouse, child or friend) who knows them well to each of the four visits
AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.
The exclusion criteria are
- Individuals with any of the following conditions/ diseases will be excluded:
Obstructive sleep apnea (OSA) without CPAP use, chronic obstructive pulmonary disease, emphysema, major psychiatric disease (bipolar, schizophrenia), history of alcohol/drug abuse, neurodegenerative disease diagnosis (e.g. Parkinson's, Lewy body, ALS, MS), prior history of stroke or traumatic brain injury, have undergone chemotherapy in the past 2 years, have been hospitalized for injury/surgery in the past three-months.
- CDR>=1, clinically significant depression/anxiety (GDS>=9; GAI>=9 ),
- Participants who are on any of the following medications will be excluded: Fluvoxamine (Luvox)/ Fluoxetine (Prozac), Nifedipine (a blood pressure medication), all anti-coagulants (e.g. Warfarin, Coumadin, Heparin, , Lovenox, Xarelto, Pradaxa, etc.), anti-seizure drugs (e.g. Acetazolamide, Carbamazepine, Clobazam, Clonazepam, Gabapentin, etc.), muscle relaxants (e.g.Baclofen, Valium/ diazepam, Flexeril, etc.), or narcotic pain relievers (e.g.Codeine, Tramadol, Hydrocodone, Demerol, etc).
Recruiting US locations
University of Iowa Hospitals & Clinics
Iowa City, IA 52242
Site contact: Natalie Denburg, Ph.D. · 3193846050 · natalie-denburg@uiowa.edu
Study contacts (from the official record)
- Natalie Denburg, Ph.D · 3193846050 · natalie-denburg@uiowa.edu
Similar studies in Iowa
All neurology studies in Iowa →- RecruitingHealthy volunteers
An Early Prospective Study of the Traq™ Device for Characterization of Binocular Ocular Function in Normal Subjects and Subjects With Recent Traumatic Brain Injury
Rebiscan, Inc.
- Location
- Waukee, IA
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Iowa City, IA + 35 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc
- Location
- Iowa City, IA + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- West Des Moines, IA + 111 other US sites
- Eligibility basics
- Ages 18+